Should prophylactic granulocyte-colony stimulating factor be used in multiple myeloma patients developing neutropenia under lenalidomide-based therapy?

British Journal of Haematology

Volumn 140, Issue 3, 2008, Pages 324-326

  Mateos, María Victoria ^a   García Sanz, Ramón ^a   Colado, Enrique ^a   Olazábal, Juan ^a   San Miguel, Jesús ^a,b  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

Dexamethasone; Granulocyte colony stimulating factor; Lenalidomide; Multiple myeloma; Neutropenia

Indexed keywords

CARMUSTINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; LENALIDOMIDE; MELPHALAN; PREDNISONE; THALIDOMIDE; VINCRISTINE;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CASE REPORT; COMBINATION CHEMOTHERAPY; DRUG MEGADOSE; FEMALE; HUMAN; INFECTION; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUTROPENIA; PRIORITY JOURNAL; THERAPY DELAY; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DEXAMETHASONE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; GRANULOCYTE COLONY STIMULATING FACTOR, RECOMBINANT; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEUTROPENIA; THALIDOMIDE; TREATMENT OUTCOME;

EID: 38349124445     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2007.06946.x     Document Type: Article

References (10)

1. Aapro, M.S., Cameron, D.A., Pettengell, R., Bohlius, J., Crawford, J., Ellis, M., Kearney, N., Lyman, G.H., Tjan-Heijnen, V.C., Walewski, J., Weber, D.C., Zielinski, C. European Organisation for Research and Treatment of Cancer (EORTC) Granulocyte Colony-Stimulating Factor (G-CSF) Guidelines Working Party (2006) EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. European Journal of Cancer, 42, 33 53.
2. Bladé, J., Samson, D., Reece, D., Apperley, J., Björkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S. Vesole, D. (1998) Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. British Journal of Haematology, 102, 1115 1123.
3. Dimopoulos, M.A., Spencer, A., Attal, A., Prince, M., Harousseau, J-L., Dmoszynska, A., Yu, Z., Olesnyckyj, M., Zeldis, J. Knight, R. (2005) Study of lenalidomide plus dexamethasone versus dexamethasone alone in relapsed or refractory multiple myeloma (MM): results of a phase 3 study (MM-010). Blood (ASH Annual Meeting Abstracts), 106, Abstract 6.
4. Hirbe, A.C., Uluçkan, O., Morgan, E.A., Eagleton, M.C., Prior, J.L., Piwnica-Worms, D., Trinkaus, K., Apicelli, A. Weilbaecher, K. (2007) Granulocyte colony-stimulating factor enhances bone tumor growth in mice in an osteoclast-dependent manner. Blood, 109, 3424 3431.
5. Kalmadi, S., Baz, R. Mahindra, A. (2007) Lenalidomide: the emerging role of a novel targeted agent in malignancies. Drugs of Today (Barcelona, Spain), 43, 85 95.
6. Kastritis, E. Dimopoulos, M.A. (2007) The evolving role of lenalidomide in the treatment of hematologic malignancies. Expert Opinion on Pharmacotherapy, 8, 497 509.
7. Richardson, P.G., Schlossman, R.L., Weller, E., Hideshima, T., Mitsiades, C., Davies, F., LeBlanc, R., Catley, L.P., Doss, D., Kelly, K., McKenney, M., Mechlowicz, J., Freeman, A., Deocampo, R., Rich, R., Ryoo, J.J., Chauhan, D., Balinski, K., Zeldis, J. Anderson, K.C. (2002) Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood, 100, 3063 3067.
8. Richardson, P.G., Blood, E., Mitsiades, C.S., Jagannath, S., Zeldenrust, S.R., Alsina, M., Schlossman, R.L., Rajkumar, S.V., Desikan, K.R., Hideshima, T., Munshi, N.C., Kelly-Colson, K., Doss, D., McKenney, M.L., Gorelik, S., Warren, D., Freeman, A., Rich, R., Wu, A., Olesnyckyj, M., Wride, K., Dalton, W.S., Zeldis, J., Knight, R., Weller, E. Anderson, K.C. (2006) A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 108, 3458 3464.
9. Tigue, C.C., McKoy, J.M., Evens, A.M., Trifilio, S.M., Tallman, M.S. Bennett, C.L. (2007) Granulocyte-colony stimulating factor administration to healthy individuals and persons with chronic neutropenia or cancer: an overview of safety considerations from the Research on Adverse Drug Events and Reports project. Bone Marrow Transplantation, 40, 185 192.
10. Weber, D., Wang, M., Chen, C., Belch, A., Stadtmauer, E.A., Niesvisky, R., Yu, Z., Olesnyckyj, M., Zeldis, J., Knight, R.D. Dimopoulos, M. (2006) Lenalidomide plus high-dose dexamethasone provides improved overall survival compared to high-dose dexamethasone alone for relapsed or refractory multiple myeloma (MM): results of 2 phase III studies (MM-009, MM-010) and subgroup analysis of patients with impaired renal function. Blood (ASH Annual Meeting Abstracts), 108, Abstract 3547.